Page last updated: 2024-11-11
pd 90780
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PD 90780: a nonpeptide inhibitor of nerve growth factor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9885305 |
CHEMBL ID | 137953 |
SCHEMBL ID | 2727308 |
MeSH ID | M0254622 |
Synonyms (22)
Synonym |
---|
bdbm50029495 |
7-benzoylamino-4-methyl-9-oxo-4,9-dihydro-pyrazolo[5,1-b]quinazoline-2-carboxylic acid |
CHEMBL137953 , |
pd 90780 |
SCHEMBL2727308 |
IAZAGXDMMVWYKF-UHFFFAOYSA-N , |
7-(benzoylamino)-4,9-dihydro-4-methyl-9-oxopyrazolo-[5,1-b]quinazoline-2-carboxylic acid |
AKOS025142048 |
7-(benzoylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid |
77422-99-2 |
pd90780 |
7-benzamido-4-methyl-9-oxo-4,9-dihydropyrazolo[5,1-b]quinazoline-2-carboxylic acid |
NCGC00386708-02 |
pd-90780;pd 90780 |
BCP16228 |
HY-110166 |
7-benzamido-4-methyl-9-oxopyrazolo[5,1-b]quinazoline-2-carboxylic acid |
CS-0033028 |
MS-25748 |
NCGC00386708-01 |
CDA42299 |
E98677 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
High affinity nerve growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 47.0000 | 0.0002 | 0.5436 | 10.0000 | AID1322459 |
Tumor necrosis factor receptor superfamily member 16 | Homo sapiens (human) | IC50 (µMol) | 55.1000 | 0.2000 | 1.9600 | 3.7200 | AID1322457; AID147189 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (69)
Molecular Functions (21)
Ceullar Components (25)
Bioassays (12)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1322458 | Inhibition of mouse NGF binding to p75 (unknown origin) by SPR method relative to control | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. |
AID182690 | Inhibition of passive cutaneous anaphylaxis (PCA) reaction in rats by intraperitoneal administration of 5 mg/kg | 1981 | Journal of medicinal chemistry, Jun, Volume: 24, Issue:6 | Pyrazolo[5,1-b]quinazolin-9-ones: a new series of antiallergic agents. |
AID1322460 | Inhibition of mouse NGF binding to TrkA (unknown origin) by SPR method relative to control | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. |
AID1322457 | Inhibition of mouse NGF binding to p75 (unknown origin) by SPR method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. |
AID182824 | Inhibition of passive cutaneous anaphylaxis (PCA) reaction in rats, peroral administration 5 mg/kg | 1981 | Journal of medicinal chemistry, Jun, Volume: 24, Issue:6 | Pyrazolo[5,1-b]quinazolin-9-ones: a new series of antiallergic agents. |
AID1322459 | Inhibition of mouse NGF binding to TrkA (unknown origin) by SPR method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. |
AID147189 | Inhibition of [125I]- NGF binding to extracellular domain of p75 receptor | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 2 (14.29) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 5 (35.71) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.23
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.23) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (7.14%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (92.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |